scholarly journals Arxula adeninivorans xanthine oxidoreductase and its application in the production of food with low purine content

2013 ◽  
Vol 115 (3) ◽  
pp. 796-807 ◽  
Author(s):  
D.A. Jankowska ◽  
A. Trautwein-Schult ◽  
A. Cordes ◽  
P. Hoferichter ◽  
C. Klein ◽  
...  
Keyword(s):  
Arxula Adeninivorans ◽  
Xanthine Oxidoreductase ◽  
Purine Content

Arxula adeninivorans recombinant adenine deaminase and its application in the production of food with low purine content

2013 ◽  
Vol 115 (5) ◽  
pp. 1134-1146 ◽  
Author(s):  
D.A. Jankowska ◽  
K. Faulwasser ◽  
A. Trautwein-Schult ◽  
A. Cordes ◽  
P. Hoferichter ◽  
...  
Keyword(s):  
Arxula Adeninivorans ◽  
Purine Content ◽  
Adenine Deaminase

Arxula adeninivorans Recombinant Guanine Deaminase and Its Application in the Production of Food with Low Purine Content

2014 ◽  
Vol 24 (2) ◽  
pp. 67-81 ◽  
Author(s):  
Anke Trautwein-Schult ◽  
Dagmara Jankowska ◽  
Arno Cordes ◽  
Petra Hoferichter ◽  
Christina Klein ◽  
...  
Keyword(s):  
Arxula Adeninivorans ◽  
Guanine Deaminase ◽  
Purine Content

scholarly journals Inorganic nitrate attenuates cardiac dysfunction: role for xanthine oxidoreductase and nitric oxide

2021 ◽  
Author(s):  
Lorna C. Gee ◽  
Gianmichele Massimo ◽  
Clement Lau ◽  
Christopher Primus ◽  
Daniel Fernandes ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Cardiac Dysfunction ◽  
Xanthine Oxidoreductase ◽  
Inorganic Nitrate

scholarly journals AB0049 RELATIONSHIP OF RHEUMATOID FACTOR AND XANTHINE OXIDOREDUCTASE ENZYMATIC CONSTITUENTS IN SEVERAL BLOOD COMPARTMENTS OF RHEUMATOID ARTHRITIC PATIENTS

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 1057.1-1057
Author(s):  
S. Bedina ◽  
A. Trofimenko ◽  
E. Mozgovaya ◽  
M. Mamus ◽  
S. Spitsina
Keyword(s):  
Blood Plasma ◽  
Rheumatoid Factor ◽  
Xanthine Oxidase ◽  
Xanthine Dehydrogenase ◽  
Enzymatic Activities ◽  
Systemic Autoimmune Disease ◽  
Ros Generation ◽  
Reference Ranges ◽  
Xanthine Oxidoreductase ◽  
In Blood Plasma

Background:Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by the presence of rheumatoid factor (RF) and anticitrulline autoantibodies. Recent evidences suggest that impairment of neutrophil extracellular traps (NETs) could exert substantial influence on RA pathogenesis. The production of NETs depends heavily on the ROS generation. One of its mechanisms is xanthine oxidoreductase (XOR) mediated degradation of purine metabolites. Analysis of pro-oxidant activity of the enzymatic complex XOR and its constituents, xanthine oxidase (XO) and xanthine dehydrogenase (XDG), is an issue of considerable interest in this context.Objectives:Evaluation of XO and XDG activities in RF-positive and RF-negative RA using both plasma and lysed lymphocyte samples.Methods:The research was carried out in agreement with the WMA Declaration of Helsinki principles. Diagnosis of RA had been verified using ACR/EULAR 2010 criteria. Enzymatic activities in plasma and lymphocytes were measured spectrophotometrically and expressed as nmol/min/ml. Enzymatic activities in lymphocytes were also normalized to 1×107 cells/ml. Statististical tests were selected in line with common guidelines. Differences were considered significant when p<0.05. Reference ranges were calculated as means ±2SD.Results:75 adult RA patients (52 females and 23 males, mean age 43.9±0.97 years, mean disease duration 8.5±0.3 years) from the rheumatology unit of Volgograd Clinical Emergency Hospital #25 as well as 35 healthy controls were included in the study. RF-positive RA and RF-negative RA were observed in 49 (65.3%) and 26 (34.7%) patients, respectively. Reference ranges for plasma and lymphocyte XO activities were 2.60-3.96 and 14.2-27.8 nmol/min/ml, respectively. Similar ranges for XDG activities were 4.49-5.93 and 22.5-40.7 nmol/min/ml, respectively. Enzymatic profile of RA patients is characterized by significantly increased XO activity in plasma and decreased XO and XDG activities in lymphocytes (р<0.001). XO activity is increased (p<0.001), XDG activity is decreased (p<0.001) in blood plasma of patients with RF-negative RA, while the activity of both enzymes is decreased in lymphocytes (p<0.001). XO activity (p<0.001) and XDG activity (p<0.05) is increased in blood plasma, XO activity and XDG activity are decreased (p<0.001) in lymphocytes of patients with RF-positive RA. Plasma XO and XDG activities are also higher, and lymphocyte XO and XDG activities are lower in patients with RF-positive RA than in patients with RF-negative RA (р<0.001).Conclusion:Our study revealed the relationship between enzyme parameters and rheumatoid factor presence. More pronounced changes in the enzyme activities were observed in patients with RF-positive RA. These results demonstrate that activation of the xanthine oxidase/xanthine dehydrogenase enzyme complex is an substantial factor of induction and continuation of the autoimmune rheumatoid inflammation.Disclosure of Interests:None declared

Omeprazole induces vascular remodeling by mechanisms involving xanthine oxidoreductase and matrix metalloproteinase activation

2021 ◽  
pp. 114633
Author(s):  
Renato C. Nogueira ◽  
Lucas C. Pinheiro ◽  
Jessica M. Sanches-Lopes ◽  
Juliana M. Parente ◽  
Gustavo H. Oliveira-Paula ◽  
...  
Keyword(s):  
Matrix Metalloproteinase ◽  
Vascular Remodeling ◽  
Xanthine Oxidoreductase

scholarly journals A novel enzymatic approach in the production of food with low purine content usingArxula adeninivoransendogenous and recombinant purine degradative enzymes

Bioengineered ◽  
2015 ◽  
Vol 6 (1) ◽  
pp. 20-25 ◽  
Author(s):  
Dagmara A Jankowska ◽  
Anke Trautwein-Schult ◽  
Arno Cordes ◽  
Rüdiger Bode ◽  
Keith Baronian ◽  
...  
Keyword(s):  
Purine Content ◽  
Degradative Enzymes

scholarly journals Inhibition of Xanthine Oxidoreductase Enhances the Potential of Tyrosine Kinase Inhibitors against Chronic Myeloid Leukemia

Antioxidants ◽  
2020 ◽  
Vol 9 (1) ◽  
pp. 74 ◽  
Author(s):  
Marta Romo-González ◽  
Sara Moreno-Paz ◽  
Violeta García-Hernández ◽  
Fermín Sánchez-Guijo ◽  
Ángel Hernández-Hernández
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Myeloid Leukemia ◽  
Kinase Inhibitors ◽  
Therapeutic Potential ◽  
Therapeutic Option ◽  
Single Agent ◽  
Signaling Cascade ◽  
Xanthine Oxidoreductase

Chronic myeloid leukemia (CML) is characterized by the expression of the oncogenic kinase BCR-ABL. Although tyrosine kinase inhibitors (TKIs) against BCR-ABL represent the standard therapeutic option for CML, resistances to TKIs can be a serious problem. Thus, the search for novel therapeutic approaches is still needed. CML cells show an increased ROS production, which is required for maintaining the BCR-ABL signaling cascade active. In line with that, reducing ROS levels could be an interesting therapeutic strategy for the clinical management of resistant CML. To analyze the therapeutic potential of xanthine oxidoreductase (XOR) in CML, we tested the effect of XOR inhibitor allopurinol. Here, we show for the first time the therapeutic potential of allopurinol against BCR-ABL-positive CML cells. Allopurinol reduces the proliferation and clonogenic ability of the CML model cell lines K562 and KCL22. More importantly, the combination of allopurinol with imatinib or nilotinib reduced cell proliferation in a synergistic manner. Moreover, the co-treatment arms hampered cell clonogenic capacity and induced cell death more strongly than each single-agent arm. The reduction of intracellular ROS levels and the attenuation of the BCR-ABL signaling cascade may explain these effects. Finally, the self-renewal potential of primary bone marrow cells from CML patients was also severely reduced especially by the combination of allopurinol with TKIs. In summary, here we show that XOR inhibition is an interesting therapeutic option for CML, which can enhance the effectiveness of the TKIs currently used in clinics.

scholarly journals Xanthine oxidoreductase inhibitor topiroxostat ameliorates podocyte injury by inhibiting the reduction of nephrin and podoplanin

Nefrología ◽  
2021 ◽  
Author(s):  
Ying Zhang ◽  
Yoshiyasu Fukusumi ◽  
Mutsumi Kayaba ◽  
Takashi Nakamura ◽  
Ryusuke Sakamoto ◽  
...  
Keyword(s):  
Xanthine Oxidoreductase ◽  
Podocyte Injury ◽  
Xanthine Oxidoreductase Inhibitor

scholarly journals Influence of xanthine oxidoreductase inhibitor, topiroxostat, on body weight of diabetic obese mice

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Takashi Nakamura ◽  
Mai Nampei ◽  
Takayo Murase ◽  
Etsuko Satoh ◽  
Seigo Akari ◽  
...  
Keyword(s):  
Body Weight ◽  
Food Intake ◽  
Ketone Body ◽  
The Body ◽  
Xanthine Oxidoreductase ◽  
Diabetic Mellitus ◽  
Triglyceride Content ◽  
Xanthine Oxidoreductase Inhibitor ◽  
Single Regression ◽  
Muscle Triglyceride

AbstractPlasma xanthine oxidoreductase (XOR) activity is high in metabolic disorders such as diabetic mellitus, obesity, or overweight. Thus, this study investigated whether the XOR inhibitor, topiroxostat, affected body weight. Male db/db mice were fed standard diets with or without topiroxostat for 4 weeks. Body weight and food intake were constantly monitored, along with monitoring plasma biochemical markers, including insulin and XOR activity. Additionally, hepatic hypoxanthine and XOR activity were also documented. Single regression analysis was performed to determine the mechanism. Topiroxostat treatment suppressed weight gain relative to the vehicle without any impact on food intake. However, the weight of fat pads and hepatic and muscle triglyceride content did not change. Topiroxostat decreased the plasma uric acid and increased hepatic hypoxanthine in response to the inhibition of XOR activity. Plasma ketone body and free fatty acid were also increased. Moreover, fat weight was weakly associated with plasma XOR activity in the diabetic state and was negatively associated with ketone body by topiroxostat. These results suggested that topiroxostat amplified the burning of lipids and the salvage pathway, resulting in predisposing the body toward catabolism. The inhibition of plasma XOR activity may contribute to weight loss.

ROLE OF XANTHINE OXIDOREDUCTASE IN EXPERIMENTAL ACUTE RENAL-ALLOGRAFT REJECTION

2004 ◽  
Vol 77 (11) ◽  
pp. 1683-1692 ◽  
Author(s):  
Kai Sun ◽  
Eva Kiss ◽  
Jens Bedke ◽  
Tomislav Stojanovic ◽  
Yanhua Li ◽  
...  
Keyword(s):  
Allograft Rejection ◽  
Renal Allograft ◽  
Xanthine Oxidoreductase ◽  
Renal Allograft Rejection ◽  
Acute Renal Allograft Rejection
Sign in / Sign up

Export Citation Format

Share Document